On March 29, 2021 Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, reported that Mike Handley, President and Chief Executive Officer, will present at the Spring 2021 meeting of the Virtual Oncology Investor Conference, sponsored by the National Foundation for Cancer Research, taking place March 29, 2021 to April 1, 2021 (Press release, Cytocom, MAR 29, 2021, https://www.cytocom.com/2021/03/29/cytocom-to-present-at-the-spring-2021-virtual-oncology-investor-conference/ [SID1234577278]). The presentation will be available for all registered attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Mr. Handley will provide an overview of Cytocom’s business and recent corporate achievements, as well as the anticipated near-term milestones in clinical programs for COVID-19, pancreatic cancer and Crohn’s disease.

Details of Cytocom’s presentation are as follows:

Event: Spring 2021 Oncology Investor Conference
Date: Tuesday, March 30, 2021
Time: 11:50 a.m. ET
Registration: View Source

Members of the Cytocom’s management team will also be available to participate in virtual one-on-one meetings with investors and representatives of biotechnology and pharmaceutical companies who are registered to attend the conference. Following the conclusion of the event, a recording of Mr. Handley’s presentation will be available under "Recent Presentations" in the Investors section of the Company’s website at www.cytocom.com.